2. Academic Validation
  3. Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors

Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors

  • ACS Med Chem Lett. 2013 Jan 15;4(2):259-63. doi: 10.1021/ml300351e.
Jin-Jun Liu 1,  Brian Higgins 1,  Grace Ju 1,  Kenneth Kolinsky 1,  Kin-Chun Luk 1,  Kathryn Packman 1,  Giacomo Pizzolato 1,  Yi Ren 1,  Kshitij Thakkar 1,  Christian Tovar 1,  Zhuming Zhang 1,  Peter M Wovkulich 1
Affiliations

Affiliation

  • 1 Discovery Chemistry, Discovery Oncology, and Chemical Synthesis, Hoffmann-La Roche Inc. , 340 Kingsland Street, Nutley, New Jersey 07110, United States.
PMID: 24900658 DOI: 10.1021/ml300351e
Abstract

A new series of 7,8-disubstituted pyrazolobenzodiazepines based on the lead compound 1 have been synthesized and evaluated for their effects on mitosis and angiogenesis. Described herein is the design, synthesis, SAR, and antitumor activity of these compounds leading to the identification of R1530, which was selected for clinical evaluation.

Keywords

FGFr and PDGFr-β; VGFr-2; antitumor effect; mitosis/angiogenesis inhibitor; pyrazolobenzodiazepines.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z